A research group involving the DZNE has successfully developed a new method of gene regulation that permanently reduces the protein "tau" in the adult brain. This could become the basis for new therapies against Alzheimer's and other neurodegenerative diseases.
The DZNE and Eisai Co., Ltd. announce that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders.
According to current studies, the COVID-19 disease which is caused by the SARS-CoV-2 coronavirus comprises at least five different variants. Researchers from the DZNE and the University of Bonn report on this in the scientific journal “Genome Medicine”.
A new app will now allow people with ataxia to assess the severity of their disease at home. It is based on the well-known SARA score, which DZNE researchers have now been able to bring into use outside of clinics.
The DZNE is a founding member of CURE-ND, a cluster of European research institutions that aim to jointly address the challenge of neurodegenerative diseases.
Michela Deleidi, a Parkinson’s researcher at the DZNE’s Tübingen site, has been awarded a “Consolidator Grant” of the European Research Council worth about two million euros.
Welcome to our website, here you can inform yourself basically cookie-free.
We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.
